



Omics Approaches to Study Extracellular Vesicles for Diagnosis and Treatment of Cancer 2.0

Guest Editor:

Dr. Zoran Minic

Department of Chemistry and
Biomolecular Sciences, John L.
Holmes Mass Spectrometry
Facility, Faculty of Science,
University of Ottawa, Ottawa, ON
K1N6N5, Canada

Deadline for manuscript
submissions:

closed (31 March 2024)

Message from the Guest Editor

Within the last decade, extracellular vesicles (EVs) have been recognized as a new mechanism of intercellular communication through the delivery of bioactive molecules such as proteins, metabolites, lipids, and nucleic acids, including messenger RNAs (mRNAs) and microRNAs (miRNAs). Their essential role in cancer biology has been highlighted in several recent studies. Cancer cell-derived EVs promote tumor progression by modulating the immune response, reprogramming the tumor microenvironment, and stimulating metastasis. Profiling the contents of EVs may further elucidate their role in cancer progression, early detection, and identification of therapeutic targets. New advancements in omics-based techniques such as genomics, transcriptomics, proteomics, and metabolomics, have contributed to a deeper understanding of molecular mechanisms through which EVs influence cancer biology. Therefore, the purpose of this Special Issue is to publish omics-based approaches studying extracellular vesicles to advance diagnosis and treatment of cancer on a molecular level.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)